5-amino-1mq Capsules

Cellular senescence is the foundation of organismal aging. In vitro cellular senescence models (such as senescence models of human fibroblasts, hepatocytes, and nerve cells) are common tools for studying aging mechanisms and interventional drugs. The active ingredient of the product can delay cellular senescence via in vitro administration.
In studies using human fibroblast senescence models, the contents of the product were dissolved and added to the culture system at various concentrations.

Results showed that the ingredient significantly increased NAD+ levels in senescent fibroblasts, activated the SIRT1 signaling pathway, reduced the expression of senescence-associated β-galactosidase (SA-β-gal), decreased intracellular reactive oxygen species accumulation, and promoted collagen synthesis. It also improved the proliferative and secretory functions of fibroblasts and reversed morphological abnormalities of senescent cells (such as flattened cell shape, enlarged volume, and nuclear pyknosis).

These studies indicate that 5-amino-1mq can delay skin fibroblast senescence by regulating NAD+ metabolism, providing a novel intervention target for skin anti-aging research. The standardized nature of the capsule formulation ensures precise dosage control in in vitro experiments and reduces experimental errors.

In neuronal senescence model studies, the active ingredient of the product can cross the blood-brain barrier (and act directly on neurons in vitro), increase NAD+ levels in nerve cells, protect mitochondrial function, reduce neuronal apoptosis, and promote the synthesis and release of neurotransmitters (such as dopamine and acetylcholine), thereby improving signal transduction in nerve cells.

Related experiments showed that after treatment with 5-amino-1mq, the survival rate of senescent neurons was significantly increased and intracellular ROS levels were markedly reduced. This provides an important tool for research into aging-related neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, and offers experimental evidence for intervention strategies in neuronal aging. Furthermore, the specific inhibition of NNMT by 5-amino-1mq avoids interference with other metabolic enzymes, ensuring the specificity and reliability of experimental results.

Animal aging models (such as naturally aged mice, D-galactose-induced aging mice, SAMP8 accelerated senescence mice, etc.) are core carriers for simulating human aging and verifying the efficacy of anti-aging drugs. With the advantages of convenient oral administration and precise dosing, the product have become commonly used preparations in animal anti-aging research, focusing on the following areas.

First, delaying the overall aging process of the body. In naturally aged mouse models (18–20 months old), daily oral administration of 5-amino-1mq capsules for 12 consecutive weeks significantly reduced NNMT activity and increased NAD+ levels in various tissues (liver, kidney, adipose tissue), along with markedly elevated expression of SIRT1 and SIRT3 proteins. Meanwhile, overall aging indicators were significantly improved: locomotor activity and endurance were enhanced, hair gloss increased, levels of aging-related inflammatory factors (such as TNF-α, IL-6) decreased, and the average lifespan of mice was prolonged.

This experiment confirmed that the product can delay systemic aging by regulating NAD+ metabolism, providing in vivo evidence for anti-aging interventions.
Second, improving aging-related metabolic disorders. During aging, metabolic function gradually declines, leading to insulin resistance, fat accumulation, and insufficient energy metabolism. It can improve these disorders by inhibiting NNMT.

In D-galactose-induced aging mice, oral administration of the product significantly increased NAD+ levels in liver and adipose tissue, activated mitochondrial energy metabolism pathways, improved insulin sensitivity, lowered blood glucose and lipid levels, reduced visceral fat accumulation, and increased energy expenditure, alleviating fatigue and abnormal body weight associated with aging.
Studies have shown that 5-amino-1mq significantly reduces the insulin resistance index and decreases adipocyte size in aging mice, providing new intervention strategies for aging-related metabolic diseases such as type 2 diabetes and obesity.

Third, protecting the function of aging-related tissues and organs. During aging, vital organs including the heart, liver, and kidneys undergo degenerative changes. The product can protect these organs and delay their aging by elevating NAD+ levels.
In aged rat models, oral 5-amino-1mq capsules significantly improved myocardial mitochondrial function, reduced cardiomyocyte apoptosis, decreased myocardial injury markers (such as CK-MB, cTnI), enhanced cardiac contractility, and alleviated aging-related myocardial fibrosis.

In addition, in research on aging-related muscle atrophy (sarcopenia), it can promote muscle cell proliferation and differentiation, reduce muscle cell apoptosis, and enhance muscle strength and endurance by activating the SIRT1 signaling pathway.
Experiments showed that oral administration of the preparation significantly increased grip strength, muscle mass, and muscle fiber diameter in aged mice, effectively alleviating aging-related muscle atrophy, and providing a new direction for anti-aging research on sarcopenia.

This is the most widely used quantitative analytical method for 5‑amino‑1mq capsules. It features high separation efficiency, high sensitivity, and good reproducibility, allowing accurate determination of the active ingredient content and related substances in the capsules.
Chromatographic conditions employ a C18 reversed-phase column, with acetonitrile–water solution (adjusted to an appropriate acidity with phosphoric acid) as the mobile phase. The flow rate is controlled at 0.8–1.0 mL/min, and the detection wavelength is optimized based on the characteristic absorption of 5‑amino‑1mq.

A C18 column is used with acetonitrile‑water solution containing 0.1% formic acid as the mobile phase. Electrospray ionization in positive mode and multiple reaction monitoring are applied for detection. This method accurately identifies the characteristic ion peaks of 5‑amino‑1mq and effectively eliminates interference from excipients and impurities. The detection sensitivity reaches the nanogram level, making it suitable for quantifying trace active ingredients in capsules and related pharmacokinetic studies.

This method is simple to operate and low in cost, used for rapid qualitative identification and preliminary quantitative verification.
The capsule contents are dissolved, and the absorbance is measured in a quartz cuvette at the maximum absorption wavelength of 5‑amino‑1mq. The preliminary content is calculated using a standard curve, allowing rapid screening of whether the preparation meets basic quality requirements. As an auxiliary method to HPLC, it improves the reliability of analytical results.